169 related articles for article (PubMed ID: 1442621)
1. Effectiveness and safety of bolus administration of alteplase in massive pulmonary embolism.
Diehl JL; Meyer G; Igual J; Collignon MA; Giselbrecht M; Even P; Sors H
Am J Cardiol; 1992 Dec; 70(18):1477-80. PubMed ID: 1442621
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism.
Levine M; Hirsh J; Weitz J; Cruickshank M; Neemeh J; Turpie AG; Gent M
Chest; 1990 Dec; 98(6):1473-9. PubMed ID: 2123152
[TBL] [Abstract][Full Text] [Related]
3. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group.
Goldhaber SZ; Agnelli G; Levine MN
Chest; 1994 Sep; 106(3):718-24. PubMed ID: 8082347
[TBL] [Abstract][Full Text] [Related]
4. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism.
Tebbe U; Graf A; Kamke W; Zahn R; Forycki F; Kratzsch G; Berg G
Am Heart J; 1999 Jul; 138(1 Pt 1):39-44. PubMed ID: 10385761
[TBL] [Abstract][Full Text] [Related]
5. Mechanical and enzymatic thrombolysis for massive pulmonary embolism.
De Gregorio MA; Gimeno MJ; Mainar A; Herrera M; Tobio R; Alfonso R; Medrano J; Fava M
J Vasc Interv Radiol; 2002 Feb; 13(2 Pt 1):163-9. PubMed ID: 11830622
[TBL] [Abstract][Full Text] [Related]
6. A new short infusion dosage regimen of recombinant tissue plasminogen activator in patients with venous thromboembolic disease.
Levine MN; Weitz J; Turpie AG; Andrew M; Cruickshank M; Hirsh J
Chest; 1990 Apr; 97(4 Suppl):168S-171S. PubMed ID: 2108854
[TBL] [Abstract][Full Text] [Related]
7. Safety of thrombolytic therapy in elderly patients with massive pulmonary embolism: a comparison with nonelderly patients.
Meneveau N; Bassand JP; Schiele F; Bouras Y; Anguenot T; Bernard Y; Schultz R
J Am Coll Cardiol; 1993 Oct; 22(4):1075-9. PubMed ID: 8409043
[TBL] [Abstract][Full Text] [Related]
8. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2.
Dalla-Volta S; Palla A; Santolicandro A; Giuntini C; Pengo V; Visioli O; Zonzin P; Zanuttini D; Barbaresi F; Agnelli G
J Am Coll Cardiol; 1992 Sep; 20(3):520-6. PubMed ID: 1512328
[TBL] [Abstract][Full Text] [Related]
9. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion.
Goldhaber SZ; Haire WD; Feldstein ML; Miller M; Toltzis R; Smith JL; Taveira da Silva AM; Come PC; Lee RT; Parker JA
Lancet; 1993 Feb; 341(8844):507-11. PubMed ID: 8094768
[TBL] [Abstract][Full Text] [Related]
10. Lower dosage of recombinant tissue-type plasminogen activator (rt-PA) in the treatment of acute pulmonary embolism: a systematic review and meta-analysis.
Zhang Z; Zhai ZG; Liang LR; Liu FF; Yang YH; Wang C
Thromb Res; 2014 Mar; 133(3):357-63. PubMed ID: 24412030
[TBL] [Abstract][Full Text] [Related]
11. Bolus thrombolysis in venous thromboembolism.
Agnelli G; Parise P
Chest; 1992 Apr; 101(4 Suppl):172S-182S. PubMed ID: 1555482
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of efficacy and tolerability of a thrombolytic treatment with rt-PA in acute massive pulmonary embolism in the elderly and patients under 75 years of age].
Gisselbrecht M; Diehl JL; Meyer G; Sors H
Rev Med Interne; 1997 Jul; 18(7):521-7. PubMed ID: 9255369
[TBL] [Abstract][Full Text] [Related]
13. Thrombolytic treatment (alteplase; rt-Pa) in acute massive pulmonary embolism and cardiopulmonary arrest.
Dirican A; Ozkaya S; Atas AE; Ulu EK; Kitapci I; Ece F
Drug Des Devel Ther; 2014; 8():759-63. PubMed ID: 24959070
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of low-dose tissue plasminogen activator therapy in acute pulmonary embolism.
Hezer H; Kiliç H; Abuzaina O; Hasanoǧlu HC; Karalezli A
J Investig Med; 2019 Dec; 67(8):1142-1147. PubMed ID: 31341000
[TBL] [Abstract][Full Text] [Related]
15. Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction.
Meneveau N; Schiele F; Vuillemenot A; Valette B; Grollier G; Bernard Y; Bassand JP
Eur Heart J; 1997 Jul; 18(7):1141-8. PubMed ID: 9243149
[TBL] [Abstract][Full Text] [Related]
16. Bolus, front-loaded, and accelerated thrombolytic infusions for myocardial infarction and pulmonary embolism.
Levine MN
Chest; 1991 Apr; 99(4 Suppl):128S-134S. PubMed ID: 2009809
[TBL] [Abstract][Full Text] [Related]
17. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial.
Sors H; Pacouret G; Azarian R; Meyer G; Charbonnier B; Simonneau G
Chest; 1994 Sep; 106(3):712-7. PubMed ID: 8082346
[TBL] [Abstract][Full Text] [Related]
18. [Chronic effects of 100 mg/2 hours recombinant tissue-type plasminogen activator therapy regimen for patients with acute pulmonary thromboembolism].
Li ZP; Xu B; Jiang R; Li JL; Jiang X; Sun ML; Jing ZC; Li YP
Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Mar; 41(3):224-8. PubMed ID: 23879948
[TBL] [Abstract][Full Text] [Related]
19. Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators.
Chest; 1990 Mar; 97(3):528-33. PubMed ID: 2106408
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial.
Wang C; Zhai Z; Yang Y; Wu Q; Cheng Z; Liang L; Dai H; Huang K; Lu W; Zhang Z; Cheng X; Shen YH;
Chest; 2010 Feb; 137(2):254-62. PubMed ID: 19741062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
